Apheresis as novel treatment for refractory angina with raised lipoprotein(a): a randomized controlled cross-over trial.

ABSTRACT:

Aims

To determine the clinical impact of lipoprotein apheresis in patients with refractory angina and raised lipoprotein(a) > 500 mg/L on the primary end point of quantitative myocardial perfusion, as well as secondary end points including atheroma burden, exercise capacity, symptoms, and quality of life.

Methods

We conducted a single-blinded randomized controlled trial in 20 patients with refractory angina and raised lipoprotein(a) > 500 mg/L, with 3 months of blinded weekly lipoprotein apheresis or sham, followed by crossover. The primary endpoint was change in quantitative myocardial perfusion reserve (MPR) assessed by cardiovascular magnetic resonance. Secondary endpoints included measures of atheroma burden, exercise capacity, symptoms and quality of life.

Results

SUBMITTER: Khan TZ 

PROVIDER: S-EPMC6075617 | biostudies-literature | 2017 May

REPOSITORIES: biostudies-literature